A portable ultrasound device is revolutionizing meningitis detection, sparking hope for safer infant diagnostics.
Story Snapshot
- The NEOSONICS device demonstrates high accuracy in detecting bacterial meningitis in infants.
- The tool offers a non-invasive, cost-effective alternative to lumbar puncture.
- Developed by Spanish startup Kriba, the device uses AI to analyze cerebrospinal fluid.
- Study results published in 2025 validate its use across multiple countries.
Non-Invasive Meningitis Detection: A Game Changer
The NEOSONICS ultrasound device, developed by Kriba, has demonstrated impressive accuracy in detecting bacterial meningitis in infants, with a sensitivity of 94% and specificity of 95%. This innovation provides a non-invasive alternative to the traditional lumbar puncture for cerebrospinal fluid analysis. The device was validated through a multicenter study led by ISGlobal and funded by the Bill & Melinda Gates Foundation. Results have been published in Pediatric Research, confirming its effectiveness in diverse settings.
The study involved over 200 infants up to 24 months old from Spain, Mozambique, and Morocco. The NEOSONICS device uses high-frequency ultrasound to scan infants’ open fontanelles and employs deep learning AI to detect inflammatory cells. This approach not only reduces the risks associated with lumbar punctures but also offers a practical solution for use in resource-limited environments. The trial successfully identified 17 out of 18 meningitis cases, showcasing its potential as a global health tool.
Implications for Global Health
The introduction of NEOSONICS marks a significant advancement in pediatric diagnostics, especially in low and middle-income countries where access to traditional diagnostic methods is limited. By offering a portable and cost-effective solution, this tool could potentially transform the management of bacterial meningitis, reducing the need for invasive procedures and minimizing the overuse of antibiotics. Additionally, it aligns with ongoing efforts to improve child health outcomes and reduce mortality rates in resource-poor settings.
ISGlobal, which coordinated the study, is focusing on integrating advanced AI features into the device for even more precise diagnostics. This development could pave the way for broader applications of AI-driven diagnostics in pediatrics, challenging the dominance of traditional methods and supporting the growth of innovative startups like Kriba.
Watch:
Broader Impacts and Future Directions
In the short term, the NEOSONICS device is expected to simplify clinical workflows and reduce trauma for infants and families by avoiding painful procedures. Long-term, it represents a paradigm shift toward non-invasive screening methods that can be scaled across various healthcare settings. The successful validation of this device may accelerate similar technological advancements in other medical fields, fostering a new era of AI-enhanced diagnostics.
While the device is currently validated for infants up to 24 months old, ongoing research aims to expand its applicability. Larger trials are necessary to ensure its efficacy across broader patient populations. As such innovations gain traction, they contribute to the overarching goal of achieving global health equity, supported by initiatives from organizations like the Bill & Melinda Gates Foundation and ISGlobal.
Meet My Healthy Doc – instant answers, anytime, anywhere.
Sources:
Una prueba no invasiva permite detectar la meningitis infantil con alta precisión diagnóstica
PECARN: Low Risk of Bacterial Meningitis in Young Febrile Infants
PubMed: Bacterial Meningitis Screening Tool Performs Well in Infants
Researchers develop test to diagnose bacterial meningitis faster
